Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) ; volume:20 ; number:1 ; day:3 ; month:12 ; year:2020 ; pages:1-16 ; date:12.2020
BMC cancer ; 20, Heft 1 (3.12.2020), 1-16, 12.2020
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-07690-8
- URN
-
urn:nbn:de:101:1-2021011218333780403553
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brückl, Wolfgang M.
- Ficker, Joachim H.
- Zeitler, Gloria
- SpringerLink (Online service)
Other Objects (12)
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer
Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
Firmenstudie ICI
Dessinservice ICI
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients
Über Ici et ailleurs : = On Ici et ailleurs
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer
Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
Firmenstudie ICI
Dessinservice ICI
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients
Über Ici et ailleurs : = On Ici et ailleurs
Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer
Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
Firmenstudie ICI
Dessinservice ICI
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients